



REPORTED SALES vs. PRIOR PERIOD (\$MM)

CONSUMER SEGMENT ⁽²⁾

BABY CARE

| | 2019 | | 2018 | | % Change | | |
|------|-------|------|----------|----------------------------|----------|----------------------------|----------|
| | 2019 | 2018 | Reported | Operational ⁽¹⁾ | Reported | Operational ⁽¹⁾ | Currency |
| US | \$ 91 | 120 | -24.1% | -24.1% | - | - | - |
| Intl | 326 | 352 | -7.3% | -4.9% | -2.4% | - | - |
| WW | 417 | 472 | -11.6% | -9.8% | -1.8% | - | - |

BEAUTY

| | | | | | | | |
|------|-------|-------|-------|-------|-------|---|---|
| US | 559 | 543 | 2.9% | 2.9% | - | - | - |
| Intl | 592 | 535 | 10.8% | 13.5% | -2.7% | - | - |
| WW | 1,151 | 1,078 | 6.8% | 8.1% | -1.3% | - | - |

ORAL CARE

| | | | | | | | |
|------|-----|-----|-------|-------|-------|---|---|
| US | 156 | 158 | -1.1% | -1.1% | - | - | - |
| Intl | 223 | 226 | -1.6% | 1.1% | -2.7% | - | - |
| WW | 379 | 384 | -1.4% | 0.2% | -1.6% | - | - |

OTC

| | | | | | | | |
|------|-------|-------|------|------|-------|---|---|
| US | 477 | 440 | 8.4% | 8.4% | - | - | - |
| Intl | 621 | 608 | 2.2% | 5.2% | -3.0% | - | - |
| WW | 1,098 | 1,048 | 4.8% | 6.5% | -1.7% | - | - |

WOMEN'S HEALTH

| | | | | | | | |
|------|-----|-----|-------|-------|-------|---|---|
| US | 3 | 3 | -4.0% | -4.0% | - | - | - |
| Intl | 252 | 266 | -5.4% | -1.3% | -4.1% | - | - |
| WW | 255 | 269 | -5.3% | -1.3% | -4.0% | - | - |

WOUND CARE / OTHER

| | | | | | | | |
|------|-----|-----|------|------|-------|---|---|
| US | 109 | 106 | 1.9% | 1.9% | - | - | - |
| Intl | 59 | 58 | 3.3% | 4.9% | -1.6% | - | - |
| WW | 168 | 164 | 2.4% | 3.0% | -0.6% | - | - |

TOTAL CONSUMER

| | | | | | | | |
|------|----------|-------|------|------|-------|---|---|
| US | 1,394 | 1,370 | 1.7% | 1.7% | - | - | - |
| Intl | 2,075 | 2,045 | 1.4% | 4.3% | -2.9% | - | - |
| WW | \$ 3,469 | 3,415 | 1.6% | 3.3% | -1.7% | - | - |

| | 2019 | | 2018 | | % Change | | |
|------|-----------|--------|----------|----------------------------|----------|----------------------------|----------|
| | 2019 | 2018 | Reported | Operational ⁽¹⁾ | Reported | Operational ⁽¹⁾ | Currency |
| US | \$ 277 | 306 | -9.5% | -9.5% | - | - | - |
| Intl | 977 | 1,079 | -9.5% | -3.7% | -5.8% | - | - |
| WW | 1,254 | 1,385 | -9.5% | -5.0% | -4.5% | - | - |
| US | 1,810 | 1,791 | 1.1% | 1.1% | - | - | - |
| Intl | 1,633 | 1,480 | 10.4% | 15.3% | -4.9% | - | - |
| WW | 3,443 | 3,271 | 5.3% | 7.5% | -2.2% | - | - |
| US | 462 | 472 | -2.1% | -2.1% | - | - | - |
| Intl | 673 | 684 | -1.7% | 3.7% | -5.4% | - | - |
| WW | 1,135 | 1,156 | -1.8% | 1.3% | -3.1% | - | - |
| US | 1,468 | 1,359 | 8.0% | 8.0% | - | - | - |
| Intl | 1,781 | 1,827 | -2.5% | 2.7% | -5.2% | - | - |
| WW | 3,249 | 3,186 | 2.0% | 5.0% | -3.0% | - | - |
| US | 9 | 10 | -3.8% | -3.8% | - | - | - |
| Intl | 724 | 782 | -7.5% | 0.4% | -7.9% | - | - |
| WW | 733 | 792 | -7.4% | 0.4% | -7.8% | - | - |
| US | 343 | 344 | -0.4% | -0.4% | - | - | - |
| Intl | 173 | 183 | -5.0% | -1.1% | -3.9% | - | - |
| WW | 516 | 527 | -2.0% | -0.7% | -1.3% | - | - |
| US | 4,369 | 4,282 | 2.0% | 2.0% | - | - | - |
| Intl | 5,962 | 6,035 | -1.2% | 4.3% | -5.5% | - | - |
| WW | \$ 10,331 | 10,317 | 0.1% | 3.4% | -3.3% | - | - |

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

| | THIRD QUARTER | | | | | NINE MONTHS | | | | |
|--------------------------------------------------|---------------|-------|----------|----------------------------------------|----------|-------------|-------|----------|----------------------------------------|----------|
| | 2019 | 2018 | Reported | % Change Operational ⁽¹⁾ | Currency | 2019 | 2018 | Reported | % Change Operational ⁽¹⁾ | Currency |
| PHARMACEUTICAL SEGMENT ⁽²⁾⁽⁴⁾ | | | | | | | | | | |
| IMMUNOLOGY | | | | | | | | | | |
| US | \$ 2,582 | 2,400 | 7.6% | 7.6% | - | \$ 7,124 | 6,717 | 6.1% | 6.1% | - |
| Intl | 1,129 | 998 | 13.2% | 16.8% | -3.6% | 3,304 | 3,061 | 8.0% | 13.9% | -5.9% |
| WW | 3,711 | 3,398 | 9.3% | 10.3% | -1.0% | 10,428 | 9,778 | 6.7% | 8.5% | -1.8% |
| REMICADE | | | | | | | | | | |
| US | 749 | 987 | -24.1% | -24.1% | - | 2,324 | 2,821 | -17.6% | -17.6% | - |
| US Exports ⁽³⁾ | 88 | 100 | -12.0% | -12.0% | - | 226 | 346 | -34.7% | -34.7% | - |
| Intl | 299 | 292 | 2.5% | 6.1% | -3.6% | 795 | 921 | -13.7% | -8.6% | -5.1% |
| WW | 1,136 | 1,379 | -17.6% | -16.9% | -0.7% | 3,345 | 4,088 | -18.2% | -17.0% | -1.2% |
| SIMPONI / SIMPONI ARIA | | | | | | | | | | |
| US | 313 | 281 | 11.6% | 11.6% | - | 857 | 779 | 10.0% | 10.0% | - |
| Intl | 273 | 255 | 7.3% | 9.9% | -2.6% | 816 | 823 | -0.8% | 4.6% | -5.4% |
| WW | 586 | 536 | 9.6% | 10.8% | -1.2% | 1,673 | 1,602 | 4.5% | 7.2% | -2.7% |
| STELARA | | | | | | | | | | |
| US | 1,212 | 889 | 36.3% | 36.3% | - | 3,152 | 2,460 | 28.1% | 28.1% | - |
| Intl | 487 | 421 | 15.7% | 19.5% | -3.8% | 1,509 | 1,252 | 20.5% | 27.1% | -6.6% |
| WW | 1,698 | 1,310 | 29.6% | 30.9% | -1.3% | 4,661 | 3,712 | 25.6% | 27.8% | -2.2% |
| TREMFYA | | | | | | | | | | |
| US | 221 | 143 | 54.3% | 54.3% | - | 565 | 311 | 81.7% | 81.7% | - |
| Intl | 69 | 28 | * | * | * | 177 | 58 | * | * | * |
| WW | 290 | 171 | 69.0% | 70.3% | -1.3% | 742 | 369 | * | * | * |
| OTHER IMMUNOLOGY⁽⁴⁾ | | | | | | | | | | |
| US | - | - | - | - | - | - | - | - | - | - |
| Intl | 2 | 2 | -4.4% | -3.0% | -1.4% | 8 | 7 | 13.7% | 14.4% | -0.7% |
| WW | 2 | 2 | -4.4% | -3.0% | -1.4% | 8 | 7 | 13.7% | 14.4% | -0.7% |
| INFECTIOUS DISEASES | | | | | | | | | | |
| US | 418 | 345 | 21.2% | 21.2% | - | 1,162 | 1,006 | 15.5% | 15.5% | - |
| Intl | 421 | 478 | -12.0% | -9.0% | -3.0% | 1,385 | 1,496 | -7.4% | -1.2% | -6.2% |
| WW | 839 | 823 | 1.9% | 3.6% | -1.7% | 2,547 | 2,502 | 1.8% | 5.5% | -3.7% |
| EDURANT / rilpivirine | | | | | | | | | | |
| US | 12 | 13 | -7.3% | -7.3% | - | 36 | 42 | -14.3% | -14.3% | - |
| Intl | 206 | 189 | 9.0% | 13.4% | -4.4% | 603 | 581 | 3.8% | 10.1% | -6.3% |
| WW | 218 | 202 | 7.9% | 12.1% | -4.2% | 639 | 623 | 2.6% | 8.5% | -5.9% |
| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | | | | | | | | | | |
| US | 373 | 297 | 25.4% | 25.4% | - | 1,032 | 847 | 21.8% | 21.8% | - |
| Intl | 135 | 193 | -29.8% | -28.1% | -1.7% | 534 | 613 | -12.8% | -6.5% | -6.3% |
| WW | 508 | 490 | 3.7% | 4.4% | -0.7% | 1,566 | 1,460 | 7.3% | 9.9% | -2.6% |
| OTHER INFECTIOUS DISEASES | | | | | | | | | | |
| US | 33 | 35 | -4.3% | -4.3% | - | 94 | 117 | -19.6% | -19.6% | - |
| Intl | 80 | 96 | -17.4% | -14.9% | -2.5% | 248 | 302 | -18.2% | -12.1% | -6.1% |
| WW | 113 | 131 | -13.9% | -12.1% | -1.8% | 342 | 419 | -18.6% | -14.2% | -4.4% |

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

| | THIRD QUARTER | | | | | NINE MONTHS | | | | | |
|-------------------------------------------------------------|---------------|-----------|----------|----------------------------|----------|-------------|-----------|----------|----------------------------|----------|--|
| | 2019 | 2018 | % Change | | | 2019 | 2018 | % Change | | | |
| | | | Reported | Operational ⁽¹⁾ | Currency | | | Reported | Operational ⁽¹⁾ | Currency | |
| NEUROSCIENCE | | | | | | | | | | | |
| US | 785 | 651 | 20.7% | 20.7% | - | 2,172 | 1,914 | 13.5% | 13.5% | - | |
| Intl | 810 | 839 | -3.5% | -1.4% | -2.1% | 2,590 | 2,663 | -2.7% | 2.4% | -5.1% | |
| WW | 1,595 | 1,490 | 7.1% | 8.2% | -1.1% | 4,762 | 4,577 | 4.0% | 7.0% | -3.0% | |
| <u>CONCERTA / methylphenidate</u> | | | | | | | | | | | |
| US | 84 | 57 | 48.2% | 48.2% | - | 196 | 191 | 2.9% | 2.9% | - | |
| Intl | 109 | 100 | 9.4% | 10.6% | -1.2% | 348 | 322 | 8.0% | 12.9% | -4.9% | |
| WW | 193 | 157 | 23.5% | 24.3% | -0.8% | 544 | 513 | 6.1% | 9.2% | -3.1% | |
| <u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u> | | | | | | | | | | | |
| US | 554 | 468 | 18.3% | 18.3% | - | 1,543 | 1,306 | 18.1% | 18.1% | - | |
| Intl | 297 | 281 | 5.9% | 9.4% | -3.5% | 916 | 859 | 6.7% | 13.0% | -6.3% | |
| WW | 851 | 749 | 13.7% | 15.0% | -1.3% | 2,459 | 2,165 | 13.6% | 16.1% | -2.5% | |
| <u>RISPERDAL CONSTA</u> | | | | | | | | | | | |
| US | 79 | 76 | 4.9% | 4.9% | - | 237 | 238 | -0.5% | -0.5% | - | |
| Intl | 89 | 99 | -10.5% | -7.5% | -3.0% | 292 | 321 | -9.1% | -3.2% | -5.9% | |
| WW | 167 | 175 | -3.8% | -2.2% | -1.6% | 528 | 559 | -5.4% | -2.1% | -3.3% | |
| <u>OTHER NEUROSCIENCE</u> | | | | | | | | | | | |
| US | 68 | 50 | 35.3% | 35.3% | - | 196 | 179 | 9.7% | 9.7% | - | |
| Intl | 316 | 359 | -12.5% | -11.5% | -1.0% | 1,035 | 1,161 | -10.9% | -6.8% | -4.1% | |
| WW | 384 | 409 | -6.6% | -5.8% | -0.8% | 1,231 | 1,340 | -8.2% | -4.6% | -3.6% | |
| ONCOLOGY | | | | | | | | | | | |
| US | 1,171 | 1,250 | -6.3% | -6.3% | - | 3,146 | 3,268 | -3.7% | -3.7% | - | |
| Intl | 1,590 | 1,338 | 18.8% | 22.9% | -4.1% | 4,830 | 4,087 | 18.2% | 25.2% | -7.0% | |
| WW | 2,761 | 2,588 | 6.7% | 8.8% | -2.1% | 7,976 | 7,355 | 8.4% | 12.3% | -3.9% | |
| <u>DARZALEX</u> | | | | | | | | | | | |
| US | 402 | 318 | 26.1% | 26.1% | - | 1,123 | 880 | 27.6% | 27.6% | - | |
| Intl | 363 | 180 | - | - | - | 1,045 | 561 | 86.2% | 98.7% | -12.5% | |
| WW | 765 | 498 | 53.5% | 56.6% | -3.1% | 2,168 | 1,441 | 50.4% | 55.3% | -4.9% | |
| <u>IMBRUVICA</u> | | | | | | | | | | | |
| US | 447 | 334 | 34.0% | 34.0% | - | 1,163 | 811 | 43.5% | 43.5% | - | |
| Intl | 475 | 371 | 27.6% | 33.0% | -5.4% | 1,373 | 1,101 | 24.6% | 33.0% | -8.4% | |
| WW | 921 | 705 | 30.6% | 33.5% | -2.9% | 2,536 | 1,912 | 32.6% | 37.4% | -4.8% | |
| <u>VELCADE</u> | | | | | | | | | | | |
| US | - | - | - | - | - | - | - | - | - | - | |
| Intl | 149 | 271 | -44.8% | -44.4% | -0.4% | 636 | 864 | -26.3% | -22.8% | -3.5% | |
| WW | 149 | 271 | -44.8% | -44.4% | -0.4% | 636 | 864 | -26.3% | -22.8% | -3.5% | |
| <u>ZYTIGA / abiraterone acetate</u> | | | | | | | | | | | |
| US | 233 | 527 | -55.8% | -55.8% | - | 616 | 1,420 | -56.6% | -56.6% | - | |
| Intl | 508 | 431 | 17.8% | 21.1% | -3.3% | 1,502 | 1,292 | 16.2% | 22.1% | -5.9% | |
| WW | 741 | 958 | -22.7% | -21.2% | -1.5% | 2,118 | 2,712 | -21.9% | -19.1% | -2.8% | |
| <u>OTHER ONCOLOGY</u> | | | | | | | | | | | |
| US | 91 | 71 | 26.7% | 26.7% | - | 245 | 157 | 54.7% | 54.7% | - | |
| Intl | 95 | 85 | 12.2% | 16.7% | -4.5% | 274 | 269 | 2.1% | 8.9% | -6.8% | |
| WW | 186 | 156 | 18.8% | 21.3% | -2.5% | 519 | 426 | 21.6% | 25.9% | -4.3% | |
| PULMONARY HYPERTENSION | | | | | | | | | | | |
| US | 427 | 425 | 0.5% | 0.5% | - | 1,296 | 1,215 | 6.6% | 6.6% | - | |
| Intl | 227 | 231 | -1.6% | 0.6% | -2.2% | 704 | 691 | 1.9% | 7.3% | -5.4% | |
| WW | 654 | 656 | -0.3% | 0.5% | -0.8% | 2,000 | 1,906 | 4.9% | 6.9% | -2.0% | |
| <u>OPSUMIT</u> | | | | | | | | | | | |
| US | 206 | 182 | 12.9% | 12.9% | - | 581 | 511 | 13.7% | 13.7% | - | |
| Intl | 140 | 128 | 10.1% | 13.2% | -3.1% | 419 | 381 | 10.2% | 16.4% | -6.2% | |
| WW | 347 | 310 | 11.7% | 13.0% | -1.3% | 1,001 | 892 | 12.2% | 14.9% | -2.7% | |
| <u>TRACLEER / bosentan</u> | | | | | | | | | | | |
| US | 19 | 69 | -72.4% | -72.4% | - | 121 | 208 | -41.8% | -41.8% | - | |
| Intl | 46 | 70 | -32.8% | -33.5% | 0.7% | 164 | 214 | -23.3% | -20.8% | -2.5% | |
| WW | 65 | 139 | -52.7% | -53.0% | 0.3% | 285 | 422 | -32.4% | -31.1% | -1.3% | |
| <u>UPTRAVI</u> | | | | | | | | | | | |
| US | 185 | 154 | 20.2% | 20.2% | - | 536 | 433 | 23.9% | 23.9% | - | |
| Intl | 25 | 17 | 52.1% | 58.7% | -6.6% | 75 | 49 | 52.8% | 61.5% | -8.7% | |
| WW | 210 | 171 | 23.4% | 24.0% | -0.6% | 611 | 482 | 26.8% | 27.7% | -0.9% | |
| <u>OTHER</u> | | | | | | | | | | | |
| US | 17 | 20 | -10.1% | -10.1% | - | 58 | 63 | -8.9% | -8.9% | - | |
| Intl | 15 | 16 | -15.4% | -11.6% | -3.8% | 46 | 47 | -3.0% | 5.4% | -8.4% | |
| WW | 31 | 36 | -12.6% | -10.8% | -1.8% | 103 | 110 | -6.4% | -2.9% | -3.5% | |
| CARDIOVASCULAR / METABOLISM / OTHER | | | | | | | | | | | |
| US | 955 | 1,026 | -6.9% | -6.9% | - | 2,804 | 3,230 | -13.2% | -13.2% | - | |
| Intl | 360 | 365 | -1.3% | 1.1% | -2.4% | 1,131 | 1,196 | -5.4% | -0.7% | -4.7% | |
| WW | 1,316 | 1,391 | -5.4% | -4.8% | -0.6% | 3,936 | 4,426 | -11.1% | -9.8% | -1.3% | |
| <u>XARELTO</u> | | | | | | | | | | | |
| US | 613 | 612 | 0.1% | 0.1% | - | 1,704 | 1,869 | -8.9% | -8.9% | - | |
| Intl | - | - | - | - | - | - | - | - | - | - | |
| WW | 613 | 612 | 0.1% | 0.1% | - | 1,704 | 1,869 | -8.9% | -8.9% | - | |
| <u>INVOKANA / INVOKAMET</u> | | | | | | | | | | | |
| US | 125 | 150 | -16.6% | -16.6% | - | 411 | 523 | -21.3% | -21.3% | - | |
| Intl | 55 | 40 | 33.9% | 37.8% | -3.9% | 147 | 130 | 12.3% | 17.9% | -5.6% | |
| WW | 179 | 190 | -5.8% | -5.0% | -0.8% | 558 | 653 | -14.6% | -13.4% | -1.2% | |
| <u>PROCRIT / EPREX</u> | | | | | | | | | | | |
| US | 126 | 178 | -29.6% | -29.6% | - | 387 | 523 | -26.1% | -26.1% | - | |
| Intl | 72 | 77 | -5.7% | -4.4% | -1.3% | 220 | 244 | -9.8% | -6.4% | -3.4% | |
| WW | 198 | 255 | -22.4% | -22.0% | -0.4% | 607 | 767 | -20.9% | -19.8% | -1.1% | |
| <u>OTHER</u> | | | | | | | | | | | |
| US | 91 | 86 | 8.1% | 8.1% | - | 302 | 315 | -3.8% | -3.8% | - | |
| Intl | 234 | 248 | -5.7% | -3.2% | -2.5% | 765 | 822 | -6.9% | -2.0% | -4.9% | |
| WW | 325 | 334 | -2.2% | -0.3% | -1.9% | 1,067 | 1,137 | -6.1% | -2.5% | -3.6% | |
| TOTAL PHARMACEUTICAL | | | | | | | | | | | |
| US | 6,340 | 6,097 | 4.0% | 4.0% | - | 17,705 | 17,350 | 2.0% | 2.0% | - | |
| Intl | 4,537 | 4,249 | 6.8% | 10.0% | -3.2% | 13,945 | 13,194 | 5.7% | 11.7% | -6.0% | |
| WW | \$ 10,877 | \$ 10,346 | 5.1% | 6.4% | -1.3% | \$ 31,650 | \$ 30,544 | 3.6% | 6.2% | -2.6% | |

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

| | THIRD QUARTER | | | | | NINE MONTHS | | | | |
|--------------------------------------------------|---------------|-------|----------|----------------------------------------|----------|-------------|--------|----------|----------------------------------------|----------|
| | 2019 | 2018 | Reported | % Change Operational ⁽¹⁾ | Currency | 2019 | 2018 | Reported | % Change Operational ⁽¹⁾ | Currency |
| MEDICAL DEVICES SEGMENT ⁽²⁾⁽⁵⁾ | | | | | | | | | | |
| DIABETES CARE[®] | | | | | | | | | | |
| US | \$ - | 125 | * | * | - | \$ - | 371 | * | * | - |
| Intl | - | 190 | * | * | * | - | 638 | * | * | * |
| WW | - | 315 | * | * | * | - | 1,009 | * | * | * |
| INTERVENTIONAL SOLUTIONS | | | | | | | | | | |
| US | 357 | 320 | 11.5% | 11.5% | - | 1,066 | 947 | 12.6% | 12.6% | - |
| Intl | 382 | 333 | 15.3% | 17.0% | -1.7% | 1,156 | 1,013 | 14.2% | 19.0% | -4.8% |
| WW | 741 | 653 | 13.4% | 14.3% | -0.9% | 2,223 | 1,960 | 13.4% | 15.9% | -2.5% |
| ORTHOPAEDICS | | | | | | | | | | |
| US | 1,301 | 1,284 | 1.2% | 1.2% | - | 3,950 | 3,923 | 0.7% | 0.7% | - |
| Intl | 837 | 827 | 1.2% | 4.1% | -2.9% | 2,616 | 2,700 | -3.1% | 2.0% | -5.1% |
| WW | 2,138 | 2,111 | 1.2% | 2.3% | -1.1% | 6,566 | 6,623 | -0.9% | 1.2% | -2.1% |
| HIPS | | | | | | | | | | |
| US | 204 | 201 | 1.1% | 1.1% | - | 633 | 621 | 1.8% | 1.8% | - |
| Intl | 133 | 129 | 2.7% | 5.7% | -3.0% | 428 | 432 | -0.8% | 4.7% | -5.5% |
| WW | 336 | 330 | 1.7% | 2.9% | -1.2% | 1,061 | 1,053 | 0.7% | 3.0% | -2.3% |
| KNEES | | | | | | | | | | |
| US | 209 | 215 | -2.7% | -2.7% | - | 650 | 672 | -3.3% | -3.3% | - |
| Intl | 136 | 126 | 7.9% | 10.8% | -2.9% | 435 | 438 | -0.6% | 4.4% | -5.0% |
| WW | 344 | 341 | 1.2% | 2.3% | -1.1% | 1,085 | 1,110 | -2.2% | -0.2% | -2.0% |
| TRAUMA | | | | | | | | | | |
| US | 415 | 395 | 5.1% | 5.1% | - | 1,239 | 1,196 | 3.6% | 3.6% | - |
| Intl | 262 | 259 | 1.0% | 4.2% | -3.2% | 795 | 829 | -4.1% | 1.0% | -5.1% |
| WW | 677 | 654 | 3.5% | 4.7% | -1.2% | 2,034 | 2,025 | 0.4% | 2.5% | -2.1% |
| SPINE & OTHER | | | | | | | | | | |
| US | 472 | 473 | -0.2% | -0.2% | - | 1,427 | 1,434 | -0.5% | -0.5% | - |
| Intl | 306 | 313 | -2.0% | 0.6% | -2.6% | 957 | 1,001 | -4.4% | 0.6% | -5.0% |
| WW | 778 | 786 | -0.9% | 0.1% | -1.0% | 2,384 | 2,435 | -2.1% | 0.0% | -2.1% |
| SURGERY | | | | | | | | | | |
| US | 940 | 1,016 | -7.4% | -7.4% | - | 2,867 | 3,031 | -5.4% | -5.4% | - |
| Intl | 1,371 | 1,360 | 0.8% | 3.5% | -2.7% | 4,192 | 4,283 | -2.1% | 3.2% | -5.3% |
| WW | 2,311 | 2,376 | -2.7% | -1.2% | -1.5% | 7,059 | 7,314 | -3.5% | -0.4% | -3.1% |
| ADVANCED | | | | | | | | | | |
| US | 409 | 421 | -2.8% | -2.8% | - | 1,209 | 1,216 | -0.6% | -0.6% | - |
| Intl | 602 | 555 | 8.3% | 11.2% | -2.9% | 1,811 | 1,731 | 4.6% | 10.1% | -5.5% |
| WW | 1,010 | 976 | 3.6% | 5.2% | -1.6% | 3,019 | 2,947 | 2.4% | 5.7% | -3.3% |
| GENERAL | | | | | | | | | | |
| US | 443 | 423 | 4.7% | 4.7% | - | 1,311 | 1,282 | 2.3% | 2.3% | - |
| Intl | 659 | 657 | 0.2% | 2.9% | -2.7% | 1,998 | 2,094 | -4.6% | 0.6% | -5.2% |
| WW | 1,101 | 1,080 | 1.9% | 3.6% | -1.7% | 3,309 | 3,376 | -2.0% | 1.2% | -3.2% |
| SPECIALTY | | | | | | | | | | |
| US | 88 | 172 | -48.0% | -48.0% | - | 347 | 533 | -34.9% | -34.9% | - |
| Intl | 110 | 148 | -25.0% | -23.1% | -1.9% | 383 | 458 | -16.2% | -11.1% | -5.1% |
| WW | 200 | 320 | -37.4% | -36.5% | -0.9% | 731 | 991 | -26.2% | -23.9% | -2.3% |
| VISION | | | | | | | | | | |
| US | 459 | 452 | 1.4% | 1.4% | - | 1,366 | 1,351 | 1.1% | 1.1% | - |
| Intl | 734 | 680 | 8.0% | 9.1% | -1.1% | 2,117 | 2,069 | 2.3% | 6.1% | -3.8% |
| WW | 1,193 | 1,132 | 5.4% | 6.1% | -0.7% | 3,483 | 3,420 | 1.8% | 4.1% | -2.3% |
| CONTACT LENSES / OTHER | | | | | | | | | | |
| US | 339 | 319 | 6.2% | 6.2% | - | 993 | 948 | 4.7% | 4.7% | - |
| Intl | 555 | 516 | 7.4% | 8.4% | -1.0% | 1,566 | 1,538 | 1.8% | 5.7% | -3.9% |
| WW | 893 | 835 | 7.0% | 7.6% | -0.6% | 2,559 | 2,486 | 2.9% | 5.4% | -2.5% |
| SURGICAL | | | | | | | | | | |
| US | 120 | 133 | -10.0% | -10.0% | - | 373 | 403 | -7.4% | -7.4% | - |
| Intl | 180 | 164 | 9.9% | 11.3% | -1.4% | 551 | 531 | 3.7% | 7.3% | -3.6% |
| WW | 299 | 297 | 0.9% | 1.7% | -0.8% | 923 | 934 | -1.1% | 0.9% | -2.0% |
| TOTAL MEDICAL DEVICES | | | | | | | | | | |
| US | 3,057 | 3,197 | -4.4% | -4.4% | - | 9,249 | 9,623 | -3.9% | -3.9% | - |
| Intl | 3,326 | 3,390 | -1.9% | 0.3% | -2.2% | 10,082 | 10,703 | -5.8% | -1.0% | -4.8% |
| WW | \$ 6,383 | 6,587 | -3.1% | -2.0% | -1.1% | \$ 19,331 | 20,326 | -4.9% | -2.4% | -2.5% |

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures, and therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Reported as U.S. sales

(4) Prior year amounts have been reclassified to conform to current year product disclosure

(5) Reflects LifeScan divestiture October 2, 2018